Mandate

VINGE ADVISED THE UNDERWRITERS IN RELATION TO NORDAX’S LISTING ON NASDAQ STOCKHOLM

June 22, 2015

Vinge advised Morgan Stanley & Co International plc, Carnegie Investment Bank AB (publ), Citigroup Global Markets Ltd and ABG Sundal Collier AB in relation to Nordax listing on Nasdaq Stockholm. Nordax’s principal shareholder is Vision Capital. A prospectus was published on 4 June 2015 and the first day of trading on Nasdaq Stockholm was on 17 June 2015. The price in the offering was set at SEK 45. The total value of the offering amounts to SEK 2.847 billion, assuming that the over-allotment option is exercised in full.

Nordax is a leading niche bank in the Nordic region providing unsecured consumer loans and deposit accounts to about 95,000 customers in Sweden, Norway, Finland, Denmark and Germany. As of 31 March 2015 lending to the general public amounted to SEK 10.3 billion and deposits amounted to SEK 6.5 billion.

Vinge’s team consisted mainly of responsible partner Charlotte Levin and associates Joakim Hagberg, Sabina Börjesson and Joel Wahlberg, and Axel Hedberg regarding regulatory questions.

Related

Vinge advises Atria Sverige in conjunction with an investment in Cookin Food

Atria Sverige has acquired a 25 per cent stake in the Swedish convenience food company Cookin Food Sweden AB. The transaction has been performed through the acquisition of shares in Bite Delight AB, which owns Cookin Food Sweden AB. Atria holds an option to acquire the remaining shares in Bite Delight AB after 2028.
March 04, 2026

Vinge advises Revivo Group on the acquisition of Solidenergy

Revivo Group, a portfolio company of Helix Kapital, has acquired Solidenergy, a leading provider of surface treatment services in the Norwegian market. The company operates within the energy, offshore and infrastructure sectors and is headquartered in Ågotnes outside Bergen. Solidenergy employs approximately 600 people.
March 03, 2026

Vinge has advised Oncopeptides in connection with its rights issue

Vinge has advised Oncopeptides AB (publ) in connection with a partially guaranteed rights issue which is expected to provide Oncopeptides with proceeds of approximately SEK 200 million before deduction of transaction costs.
March 03, 2026